Organotypic Models in Drug Development
Published on 26. March 2021
Book
Hardback
VIII, 323 pages
978-3-030-70062-1 (ISBN)
Description
This book provides latest findings in organotypic models in drug development and provides the scientific resonance needed in an emerging field of research in disciplines, such as molecular medicine, physiology, and pathophysiology. Today the research on human-based test systems has gained major interest and funding in the EU and the US has increased over the last years. Moreover, so-called 3R (reduce, replace, refine animal experiments) centres have been established worldwide.
More details
Series
Edition
1st ed. 2021
Language
English
Place of publication
Cham
Switzerland
Publishing group
Springer International Publishing
Target group
Professional and scholarly
Illustrations
33 s/w Abbildungen, 37 farbige Abbildungen
VIII, 323 p. 70 illus., 37 illus. in color.
Dimensions
Height: 241 mm
Width: 160 mm
Thickness: 23 mm
Weight
725 gr
ISBN-13
978-3-030-70062-1 (9783030700621)
DOI
10.1007/978-3-030-70063-8
Schweitzer Classification
Other editions
Additional editions
Monika Schäfer-Korting | Silvya Stuchi Maria-Engler | Robert Landsiedel
Organotypic Models in Drug Development
Book
03/2022
Springer
€213.99
Shipment within 7-9 days
Monika Schäfer-Korting | Silvya Stuchi Maria-Engler | Robert Landsiedel
Organotypic Models in Drug Development
E-Book
03/2021
Springer
€213.99
Available for download
Content
Inflammatory skin disease models in vitro and in animals - predictability for drug development.- Neural In Vitro Models for Studying Substances Acting on the Central Nervous System.- Quality of commercial tissues Standardised Reconstructed Skin Models in Toxicology and Pharmacology: State of the Art and Future Development.- Human-Derived In Vitro Models Used for Skin Toxicity Testing Under REACh.- Disease Models: Lung models for testing drugs against inflammation and infection.- In Vitro Models of the Blood-Brain Barrier.- How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development.- The CAM Assay as an Alternative In Vivo Model for Drug Testing.- Organotypic Models in Drug Development "Tumor Models and Cancer Systems Biology for the Investigation of Anticancer Drugs and Resistance Development.- Tissue Engineering for Musculoskeletal Regeneration and Disease Modeling.- Immunocompetent human intestinal models in preclinical drug development.- EngineeredHeart Muscle Models in Phenotypic Drug Screens.